Tesamorlin
$69.99
A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research. Premium Research Peptide.
1000 in stock
🔥 Exclusive Crypto Offer
Get an INSTANT 15% DISCOUNT when you pay with Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, XRP, Solana, or USDT.
âš¡ Don't have crypto? Buy it here in 5 minutes with easy guidance.
💡 Pro Tip: You can also pay with cryptocurrency using your verified Cash App or PayPal account for a fast and secure checkout!
Certificate of Analysis
Third Party Tested • ISO/IEC 17025 Accredited • Premium Quality
Purity: 99.61% (✓ Passed Full QC Panel)
Tesamorelin 10mg Specification
| Variant | Tesamorelin 10mg |
| Lot # | TES0002 |
| Labeled | 10mg |
| Actual | 10.38mg |
| Tested | Jun 10, 2026 |
| Full QC Panel | 8× tested |
| Purity (HPLC) | 99.61% |
| Net Peptide Content | 10.38mg |
| Identity (HPLC) | Tesamorelin |
| Fentanyl Screen | Not Detected |
| HPLC Conformity | mean 99.47% |
| Heavy Metals (ICP-MS) | Not Detected |
| Sterility (PCR) | No Growth |
| Endotoxin (USP <85>) | < 0.05 EU/mLISO/IEC 17025 AccreditedISO 170257× TestingSelected dosage98.82%Purity✓ Passed full QC panel |
Tesamorelin 10mg Specification
| Variant | Tesamorelin 10mg |
| Lot # | TES0001 |
| Labeled | 10mg |
| Actual | 10.54mg |
| Tested | May 29, 2026 |
| Full QC Panel | 7× tested |
| Purity (HPLC) | 98.82% |
| Net Peptide Content | 10.54mg |
| Identity (HPLC) | Tesamorelin |
| HPLC Conformity | mean 98.68% |
| Heavy Metals (ICP-MS) | Not Detected |
| Sterility (PCR) | No Growth |
| Endotoxin (USP <85>) | < 0.05 EU/mLISO/IEC 17025 Accredited |
Frequently Researched Together
Metabolic research compounds
Journal of Clinical Endocrinology & Metabolism
Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
2010•PMID: 20554713
Falutz J, et al.
View SourceLancet HIV
Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
2019•PMID: 31611038
Stanley TL, et al.
View SourceArchives of Neurology
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults
2012•PMID: 22869065
Baker LD, et al.
View SourceJournal of Clinical Endocrinology & Metabolism
The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
2019•PMID: 31050749
Adrian S, et al.
View SourceJCI Insight
Effects of tesamorlin on hepatic transcriptomic signatures in HIV-associated NAFLD
2020•PMID: 32780726
Fourman LT, et al.
View SourceFDA
EGRIFTA (tesamorlin) Prescribing Information
2025
Theratechnologies Inc.
View Source
Related products
Secretagogue Peptide
Secretagogue Peptide
Secretagogue Peptide